Jefferies Assumes Taysha Gene Therapies (TSHA) at Buy, Raises PT to $45
Tweet Send to a Friend
Jefferies analyst Eun Yang assumes coverage on Taysha Gene Therapies (NASDAQ: TSHA) with a Buy rating and a price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE